Nucana PLC 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ

19 Mar 2026

NCNA

Nucana PLC

20-F: NuCana Reports Increased Losses, Advances Melanoma Drug

NuCana plc reported a significant increase in net losses for 2025, reaching £29.4 million, while advancing its lead oncology candidate NUC-7738 in melanoma and evaluating future paths for NUC-3373.

NASDAQ

21 Mar 2025

NCNA

Nucana PLC

20-F: NuCana plc Releases 2024 Financial Results in Form 20-F Filing

NuCana plc reports its 2024 financial results, highlighting ongoing clinical trials and future plans in its annual Form 20-F filing.

NASDAQ

20 Mar 2024

NCNA

Nucana PLC

20-F: NuCana PLC Files 2023 Annual Report, Continues Clinical Trials Amid Financial Losses

Biopharmaceutical company NuCana PLC reported continued losses for 2023 as it advances clinical trials for its cancer treatment candidates, NUC-3373 and NUC-7738.